



# Biotech Daily

Tuesday December 15, 2009

*Daily news on ASX-listed biotechnology companies*

## **\* BIOPHARMICA'S CORTICAL DYNAMICS FINISHES MONITOR RESEARCH**

### BIOPHARMICA, CORTICAL DYNAMICS

Biopharmica subsidiary Cortical Dynamics has completed grant-funded research on its brain monitoring system for anaesthesia.

Biopharmica chairman David Breeze said that following the spin-out, his company owned 3.6 percent of Cortical Dynamics but Biopharmica shareholders owned about 62 percent of the company.

Biopharmica said the 2007 National Health and Medical Research Council grant was for 'Commercial testing of a physiologically based theory of oscillatory brain electrical activity in anaesthesia monitoring'.

The company said the grant enabled further commercial development and testing of the physiologically-based anaesthesia monitoring process which monitors brain electrical activity and was administered through Swinburne University under Prof David Liley. Biopharmica said Cortical Dynamics was developing the depth of anaesthesia monitoring system for use during major surgery and the core technology was based on real time analysis of the patients electroencephalogram using a proprietary algorithm based on a mathematically and physiologically detailed understanding of the brain's rhythmic electrical activity.

Biopharmica said the research enabled substantial improvements in the performance of the Brain Anaesthesia Response (BAR) monitor including a modified sensor layout with improved performance and sensitivity, as well as an upgrade of the data acquisition module to enable a greater resilience to the effects of noise and artefact in clinical monitoring.

The company said the hardware developments translated into significant improvements in the ability of the BAR monitor to detect a wide range of anaesthetic drug effects.

Biopharmica said the work concluded "the most important components of the system development and integration of the BAR monitor ... and will allow a full suite of testing and calibration trials to occur prior to the monitor's full production and distribution".

Biopharmica was up one cent or 6.7 percent to 16 cents.